VANFLYTA 26.5mg tablets medication leaflet

L01EX11 quizartinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors

General data about VANFLYTA 26.5mg

Substance: quizartinib

Date of last drug list: 01-02-2026

Commercial code: W71642001

Concentration: 26.5mg

Pharmaceutical form: tablets

Quantity: 56

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: DAIICHI SANKYO EUROPE GMBH - GERMANIA

Holder: DAIICHI SANKYO EUROPE GMBH - GERMANIA

Number: 1768/2023/05

Shelf life: 5 years

Concentrations available for quizartinib

17.7mg, 26.5mg